Quizartinib needs to be used in combination with chemotherapy and maintained long-term. During treatment, a range of treatment-related adverse reactions may occur.
Common Adverse Reactions (≥20%): These include lymphopenia, hypokalemia, hypoalbuminemia, hypophosphatemia, elevated alkaline phosphatase, hypomagnesemia, febrile neutropenia, diarrhea, mucositis, nausea, hypocalcemia, abdominal pain, sepsis, neutropenia, headache, elevated creatine phosphokinase, vomiting, and upper respiratory tract infection.
Serious Adverse Reactions: QT prolongation, torsades de pointes, and cardiac arrest: Quizartinib can cause dose- and concentration-dependent QT interval prolongation, which can lead to torsades de pointes, ventricular fibrillation, cardiac arrest, and sudden death.
Embryo-fetal toxicity: May cause fetal harm.
